WO1995007729A1 - Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire - Google Patents

Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire Download PDF

Info

Publication number
WO1995007729A1
WO1995007729A1 PCT/EP1994/002842 EP9402842W WO9507729A1 WO 1995007729 A1 WO1995007729 A1 WO 1995007729A1 EP 9402842 W EP9402842 W EP 9402842W WO 9507729 A1 WO9507729 A1 WO 9507729A1
Authority
WO
WIPO (PCT)
Prior art keywords
frequency
oscillators
mhz
cellular system
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1994/002842
Other languages
English (en)
Inventor
Saverio Giangregorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theta Electronics SA
Original Assignee
Theta Electronics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theta Electronics SA filed Critical Theta Electronics SA
Priority to AU76558/94A priority Critical patent/AU7655894A/en
Priority to EP94926898A priority patent/EP0669843A1/fr
Publication of WO1995007729A1 publication Critical patent/WO1995007729A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals

Definitions

  • the object of this invention is a device for stimulating the natural defenses of a person or of any cellular system, characterized by means for generating alternately electrical, magnetic and electromagnetic fields, at overlapping or sequentially ordered levels, with programmed modulations for creating therapeutic energy according to a certain code which resonates with the set of subatomic, atomic, molecular and cellular natural oscillators of an individual or of any cellular system, thus re- establishing metabolic equilibrium.
  • the device creates the optimum electromagnetic environment for improving the development and functioning of any cell, whether a human, animal or plant cell.
  • the device provides vital energy which, for many and sundry reasons, can become depleted. When this occurs, energy is transferred to those cells which need it, using very weak electromagnetic pulses which are virtually harmless to everyone.
  • this device re-establishes cellular metabolism and thus also the metabolism of the entire ailing organism, creating—especially for the ailing elderly—a general sense of well-being, and improving general physiological activity by 90-100%.
  • the device is also especially suitable for curing nerve, osteoarticular, arthritic, respiratory, blood, diabetic, and other disorders.
  • Figure 1 shows the schematic of the device
  • FIG. 2 is a block diagram. Descriptions follow which explain the device with regard to its conception.
  • the basic conceptual principle is that of "recharging" the cellular unit.
  • the transport, conversion and amplification of the signal received will allow the tissue cell or cells to respond in an appropriate manner, according to need.
  • the initial composition that is, the receiving molecule present on the surface of the cell, transmits the information over the plasma membrane and inside this cell, by means of a family of proteins which function as transducers, called G proteins.
  • G proteins activate an amplifier enzyme which is only located in the cell membrane; this transforms the precursor molecules into secondary messengers which spread out through the cell.
  • the secondary messengers trigger some cellular proteins to modify their structure, with the result that the functioning of these proteins is activated or deactivated.
  • the secondary messengers therefore, turn on or turn off the switches which control the activity of proteins, creating different conditions inside the cell. These conditions will determine the type of response the cell will give to signals received from the outside.
  • the secondary messenger bonds to a component of an enzymatic protein, triggering the activity of the component which carries out enzyme functions.
  • the mechanisms of signal transport and amplification are not necessary, while turning on or turning off the switch is done by the bond of the external signal.
  • the action of receivers which have bonded the messenger can consist in selective opening of small pores or channels specific to given ions (for example, calcium) present in the cellular membrane.
  • fat-soluble molecules steroid hormones
  • the receivers for these hormones are located in the cytoplasm.
  • proteins whose form is modified by the bond with the signal molecule.
  • the modified protein enters the nucleus and becomes able to bond to DNA, the large molecule which preserves genetic information, at certain points, where it serves to control activation of the genes present at the point at which it is bound.
  • This effect is known as primary response, in other cases secondary response, that is, the products of the primary response can have as a function—by bonding to DNA—that of activating other genes, amplifying and varying the response.
  • Another method of controlling the response is to act on the receivers. After the water-soluble hormones bond with the appropriate receivers on the surface of the target cell, the cells often ingest them by endocytosis and destroy them. In this way, since there are either the same number or a lesser number of receivers, the capacity to respond to the hormones is also diminished.
  • the receiver is "internalized” by endocytosis and preserved in vesicles, to be then reassembled on the cell membrane.
  • Figure 1 shows the schematic of the device.
  • the integrated circuit marked as IC2 acts as a pulse divider, and is a 12-stage binary device of the CMOS type.
  • the integrated circuit marked as IC1 functions as a square wave oscillator, sending its composite signal to pin 10 of integrated circuit IC2, enabling the latter to generate from outputs 1-15-14-12-13 the proper stop/start pulses.
  • the pulses will be spaced out by switch SI, which will make it possible, through passage of C18, to distinguish the signal coming from pin 5 of 1C1B.
  • IC1D is amplified by the VHF power transistor, marked as TR4.
  • TR4 VHF power transistor
  • the output frequencies of transistors TRI and TR2 are matched by impedances IMP1 and IMP2 to a single intermediate frequency which will center on 12 MHz. From transistors TRI and TR2, which function as sequential power oscillators, it is possible to obtain, by continuous emissions, those which cover a frequency range from 20 to around 350 MHz. This type of "complex" wave will generate a considerable number of harmonics, since the emission will be modulated both in amplitude and in frequency.
  • the passband which operates at a linear recurrence frequency, is around 100 MHz, and can generate much higher frequencies, emitting nonlinear square waves, with composite harmonics emitted which can reach 500 MHz.
  • the two monostable adjustable oscillators at the NOR outputs of IC3 control the visual signal at the output through capacitors C13 and C17 by means of two LED diodes, marked on the diagram as DL1 and DL2 respectively.
  • diodes DI and D2 as well as diodes D5 and D6 function as rectifiers of VHF signals, thus providing immediate display of the frequency intervals preselected, through switch SI.
  • the circuit is powered with stabilized 24V direct current, with a maximum absorption of 30/35 mA.
  • the device is installed in connection with a EUROCARD type card with dimensions of 100 x 160 mm.
  • the 64-pin DIN 41612 on two wires is used as a terminal connector.
  • the card marked with the designation 9301/M is installed in a standard 19" holder with a height equal to 3 units.
  • Figure 2 shows a block diagram in which C is the converter, I.F. is the amplifier, M the modulator, A.F. the amplifier, 0 the oscillator.
  • the signal is coded with n bits (0 or 1) , in fact is quantized in 2n levels.
  • the time function which represents the signal, is sampled through the amplifier of F.I., while the amplitude of each sample is rounded off to the nearest of 2n levels admitted for transmission.
  • the code used is binary code.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Ce dispositif stimule les défenses naturelles d'un individu ou de tout système cellulaire. Il comprend des moyens générant alternativement des champs électromagnétiques, magnétiques et électriques, dans un ordre séquentiel ou avec chevauchement, avec des modulations programmées. Ils permettent de créer une énergie thérapeutique selon un certain code qui résonne avec l'ensemble d'oscillateurs naturels subatomiques, atomiques, moléculaires et cellulaires d'un individu ou de tout système cellulaire. L'équilibre métabolique peut être ainsi ré-établi.
PCT/EP1994/002842 1993-09-13 1994-08-27 Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire Ceased WO1995007729A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU76558/94A AU7655894A (en) 1993-09-13 1994-08-27 Device for stimulating the natural defenses of a person or of any cellular system
EP94926898A EP0669843A1 (fr) 1993-09-13 1994-08-27 Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH02728/93-0 1993-09-13
CH272893 1993-09-13

Publications (1)

Publication Number Publication Date
WO1995007729A1 true WO1995007729A1 (fr) 1995-03-23

Family

ID=4240274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002842 Ceased WO1995007729A1 (fr) 1993-09-13 1994-08-27 Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire

Country Status (3)

Country Link
EP (1) EP0669843A1 (fr)
AU (1) AU7655894A (fr)
WO (1) WO1995007729A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013549A1 (fr) * 1995-10-10 1997-04-17 Suleyman Seckiner Gorgun Dispositif et procede de modulation des fonctions biologiques de structures biologiques
WO2001070334A1 (fr) * 2000-03-24 2001-09-27 Active Medical Devices S.A. Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire
FR2820327A1 (fr) * 2001-02-06 2002-08-09 Mohamed Ayari Procede pour l'obtention d'un ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques et biotechnologiques
AU751973B2 (en) * 1997-10-17 2002-09-05 Axel Muntermann Device for magnetic field therapy
WO2019178704A1 (fr) * 2018-03-20 2019-09-26 Novatech - Solutions Sa Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136530A1 (fr) * 1983-09-12 1985-04-10 Dieter-Ernst Broers Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques
US4611599A (en) * 1983-06-16 1986-09-16 Richard Hugh Cameron Bentall Electrical apparatus for influencing the metabolic characteristics of living systems
CH667210A5 (de) * 1981-11-24 1988-09-30 Meguer V Kalfaian Elektromagnetische bestrahlungsvorrichtung fuer therapeutische zwecke.
EP0500983A1 (fr) * 1991-02-28 1992-09-02 Medi-Line Gmbh Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667210A5 (de) * 1981-11-24 1988-09-30 Meguer V Kalfaian Elektromagnetische bestrahlungsvorrichtung fuer therapeutische zwecke.
US4611599A (en) * 1983-06-16 1986-09-16 Richard Hugh Cameron Bentall Electrical apparatus for influencing the metabolic characteristics of living systems
EP0136530A1 (fr) * 1983-09-12 1985-04-10 Dieter-Ernst Broers Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques
EP0500983A1 (fr) * 1991-02-28 1992-09-02 Medi-Line Gmbh Dispositif d'irradiation pour le traitement de tissu vivant par des ondes électromagnétiques

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013549A1 (fr) * 1995-10-10 1997-04-17 Suleyman Seckiner Gorgun Dispositif et procede de modulation des fonctions biologiques de structures biologiques
AU751973B2 (en) * 1997-10-17 2002-09-05 Axel Muntermann Device for magnetic field therapy
WO2001070334A1 (fr) * 2000-03-24 2001-09-27 Active Medical Devices S.A. Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire
FR2820327A1 (fr) * 2001-02-06 2002-08-09 Mohamed Ayari Procede pour l'obtention d'un ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques et biotechnologiques
WO2002062418A1 (fr) * 2001-02-06 2002-08-15 Mohamed Ayari Ensemble de champs electromagnetiques a visees diagnostiques, preventives, therapeutiques
WO2019178704A1 (fr) * 2018-03-20 2019-09-26 Novatech - Solutions Sa Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire

Also Published As

Publication number Publication date
AU7655894A (en) 1995-04-03
EP0669843A1 (fr) 1995-09-06

Similar Documents

Publication Publication Date Title
EP1575475B1 (fr) Regulation de l'expression genique du collagene de type ii au moyen de signaux electriques et electromagnetiques specifiques et selectifs
Berta et al. Extracorporeal shock waves enhance normal fibroblast proliferation in vitro and activate mRNA expression for TGF-β1 and for collagen types I and III
EP1560553B1 (fr) Régulation de l'expression du gène de l'aggrécane au moyen de signaux électriques et electromagnétiques spécifiques et sélectifs
CA2367631A1 (fr) Stimulateur cardiaque sans fil muni d'electrode-stents vasculaires
CA2308335A1 (fr) Dispositif de magnetotherapie
NZ548447A (en) Up-regulation of bone morphogenetic protein (BMP) gene expression in bone cells by electromagnetic signals
DE60044808D1 (de) Gerät zur ultraschall- und elektromagnetischen behandlung von gewebe
TW201247180A (en) Bio-medical unit system for medication control
Hagi et al. Augmenting effect of opioid peptides on murine macrophage activation
CN101306228A (zh) 电磁场与超声波复合治疗骨质疏松症的装置
EP0669843A1 (fr) Dispositifs de stimulation des defenses naturelles d'un individu ou de tout systeme cellulaire
CN201094810Y (zh) 电磁场与超声波复合治疗骨质疏松症的装置
WO1997011667A3 (fr) Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
FR2774916B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite
WO1992002201A1 (fr) Dispositif d'echange d'informations d'energie entre des objets
IT1312090B1 (it) Microrganismi inattivati comprendenti sostanze solubili e/osolubilizzabili ad attivita' farmacologica e/o sostanze nutrizionali
DE60023180D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
WO1993025576A3 (fr) Peptides ayant un facteur de croissance derive des plaquettes (pdgf)
EP3768379A1 (fr) Équipement conçu pour stimuler et optimiser la réorganisation biomoléculaire et cellulaire
WO2001070334A1 (fr) Equipement conçu pour stimuler et optimiser la reorganisation biomoleculaire et cellulaire
GB2292665A (en) Pest control RF transmitter
DK0758342T3 (da) Hidtil ukendt peptidisk aktivt stof og fremstilling heraf
CN100435884C (zh) 免疫治疗机
AU2005225011A1 (en) Electromagnetic treatment of mammals
Adams et al. Peeper creepers.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994926898

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1994926898

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1994926898

Country of ref document: EP